S669
Clinical – Head & neck
ESTRO 2026
was conducted using stratified block randomization (radical/adjuvant strata). Patients received radiotherapy dose of 66-70 Gy in 6-7 weeks with IMRT/3D CRT techniques and weekly concurrent Cisplatin of 40 mg/m2. Patients in the intervention arm received 500 mL IV fluids daily, throughout their treatment; the control arm received standard care. Outcomes included completion of ≥ 5 chemotherapy cycles with <3-day breaks, incidence and duration of grade ≥ 3 mucositis, need for nasogastric feeding, unplanned hospital admissions, and weight loss. Chemotherapy was omitted during neutropenia and/or grade > 3 toxicity. Results:
Mini-Oral 5002
Randomized Trial on effect of prophylactic daily IV fluids in patients undergoing chemoradiotherapy for head and neck cancer Megha T Philip, Rajendra Benny Kuchipudi, Jino Wilson Victor, Manu Mathew, Swathi B, Sharon Gikku George, Anjana Chandran, Hannah Mary Thomas T, Glory Ravi, Rajesh Isiah, Simon Pavamani, Balukrishna S Radiation Oncology, Christian Medical College, Vellore, India Purpose/Objective: Concurrent chemoradiotherapy is the gold standard treatment for locally advanced head and neck cancers (HNC), offering organ preservation benefits. However, toxicities such as mucositis, dysphagia, and nausea often limit oral intake, leading to dehydration and weight loss, which can compromise treatment compliance and outcomes. This study aims to evaluate whether daily prophylactic intravenous (IV) fluid supplementation improves treatment tolerance and reduces complications in HNC patients undergoing radical or adjuvant chemoradiotherapy. Material/Methods:
A randomized controlled trial (CTRI/2023/10/058708)
Made with FlippingBook - Share PDF online